PFE vs VMD

Pfizer Inc. remains a mature, large-cap pharmaceutical company with limited potential for the requested 10x growth within 3-5 years, which would require a market cap exceeding $1.4 trillion. While Q1 2026 results showed revenue of $14.45B and adjusted EPS of $0.75, both beating estimates, YoY revenue growth was modest at +5.4% and adjusted EPS declined -18%. Strategic legal wins for VYNDAQEL and C...

Viemed Healthcare Inc. continues to exhibit strong performance and strategic execution within the high-growth tech-enabled home respiratory and chronic care market. Q1 2026 results show impressive 28% YoY revenue growth and an improved gross margin. The company has no net debt and generates substantial, growing free cash flow ($36.3M TTM), supporting its active share repurchase program. Management...